COMP <GO>
TXG vs BRKR // EV/EBITDA & P/E VALUATION
10x Genomics Inc. (NASDAQ) VS. Bruker Corporation (NASDAQ) • 15-METRIC TALLY: TXG 7
— BRKR 6
■ METRIC PARITY
LAST: $70.11 (-14.03%) • MKT CAP: $10.63B
valuation
—
LAST: $57.07 (-7.95%) • MKT CAP: $9.45B
valuation
75.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. BRKR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXG | BRKR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | 45.90% | +23.20 | TXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -5.70% | 1.30% | -7.00 | BRKR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 75.7x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | 0.46% | +0.76 | TXG | /fcf-yield <GO> |
| Operating Margin | -9.50% | 2.00% | -11.50 | BRKR | /operating-margins <GO> |
| Net Profit Margin | -6.80% | -0.20% | -6.60 | BRKR | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 2.10% | +3.10 | TXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | BRKR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 25.02 | 2.81 | +22.21 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | TXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.0 | 56.2 | -1.20 | BRKR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.97 | +0.18 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 22.0x | +2.00 | BRKR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.63B | $9.45B | $1.18B | TXG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXG REV | BRKR REV | TXG GROSS % | BRKR GROSS % | TXG FCF | BRKR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | $3.44B | 69.1% | 45.9% | $130.1M | $43.3M |
| FY 2024 | $610.8M | $3.37B | 67.9% | 49.0% | -$5.7M | $136.0M |
| FY 2023 | $618.7M | $2.96B | — | — | -$43.0M | $216.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
BRKR // BETA 0.97